{"id":19690,"date":"2025-04-16T09:35:03","date_gmt":"2025-04-16T09:35:03","guid":{"rendered":"https:\/\/interhospi.com\/?p=19690"},"modified":"2025-04-16T09:35:03","modified_gmt":"2025-04-16T09:35:03","slug":"baxter-introduces-room-temperature-hemopatch-for-surgical-bleeding-control","status":"publish","type":"post","link":"https:\/\/interhospi.com\/baxter-introduces-room-temperature-hemopatch-for-surgical-bleeding-control\/","title":{"rendered":"Baxter introduces room temperature Hemopatch for surgical bleeding control"},"content":{"rendered":"
\n

<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Baxter introduces room temperature Hemopatch for surgical bleeding control<\/h1>\/ in Product News<\/a>, Surgery<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Baxter International Inc. has announced the European launch of its Hemopatch Sealing Hemostat with room temperature storage capability, eliminating the need for refrigeration and enabling immediate accessibility in operating theatres.<\/strong><\/p>\n

<\/p>\n

\"Baxter_Hemopatch\"<\/p>\n

The advanced surgical product, designed for tissue sealing, dura sealing and haemostasis, maintains its established efficacy while offering enhanced convenience for surgical teams requiring rapid access to bleeding control solutions during procedures.<\/p>\n

Optimised accessibility in critical situations<\/strong><\/h3>\n

The room temperature storage innovation represents a significant advancement in surgical haemostats, developed in direct response to surgeon feedback and real-world clinical needs.<\/p>\n

\u201cFor over a decade, Hemopatch Sealing Hemostat has offered surgeons a reliable solution for tissue sealing, dura sealing, and hemostasis,\u201d said Steve Wallace, president, Advanced Surgery at Baxter. \u201cThe product evolution to include room temperature storage is a result of close collaboration between surgeons and Baxter. Removing the need for refrigeration addresses the needs of our customers to have the product on hand in critical situations. We are proud to continue Baxter\u2019s legacy of innovation in sealing and haemostasis.\u201d<\/p>\n

The improved Hemopatch, announced at a symposium in Austria, is now available for order throughout Europe, providing surgeons with greater flexibility in both inventory management and point-of-care access.<\/p>\n

Clinical effectiveness in multiple surgical specialties<\/strong><\/h3>\n

Hemopatch Sealing Hemostat is a ready-to-use absorbable collagen pad with demonstrated effectiveness in both open and minimally invasive surgical procedures. Registry data from across Europe has shown it achieves rapid and sustainable haemostasis across numerous surgical specialties.<\/p>\n

The product\u2019s structure \u2013 consisting of bovine dermis collagen coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate) \u2013 creates a flexible pad that surgeons can precisely control during application. For easy identification during procedures, the non-coated side features blue squares using biocompatible colourant.<\/p>\n

Surgeon perspective on practical benefits<\/strong><\/h3>\n

General Surgeon, Prof. Dr. med. Selman Uran\u00fcs, who has extensive experience with the product, commented on the significance of the enhancement: \u201cMore than 10 years ago, I first used Hemopatch Sealing Hemostat for experimental testing. Since then, I have been using it in my daily practice because of its unique characteristics as a sealing haemostatic patch, especially in laparoscopic surgery. In my opinion, eliminating the need for refrigeration and increasing product shelf life are crucial improvements because it enables surgeons to have the product available in the operating room when it matters most. After application, the product shows an enhanced adhesive strength supporting us surgeons to achieve better surgical outcomes.\u201d<\/p>\n

Clinical indications and considerations<\/strong><\/h3>\n

Hemopatch is indicated as a haemostatic device and surgical sealant for various soft tissues including cardiovascular, connective tissue, parenchyma, serosa, and viscera. It\u2019s specifically designed for situations where controlling mild or moderate bleeding by conventional surgical techniques is either ineffective or impractical.<\/p>\n

Additionally, the product may be used to augment dura closure techniques for small dural defects (\u22643mm) following traumatic injury, excision, retraction or shrinkage of the dura mater.<\/p>\n

Important safety considerations include avoiding use in pulsatile or severe bleeding, active infections, and exercising caution when using near the spinal cord, brain, or cranial nerves due to potential expansion upon absorption of liquid.<\/p>\n